26.11.2021 - (PLX AI) – Novo Nordisk announces impact from Volume Based Procurement for insulin in China.Novo Nordisk expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin .